Malhi GS, Mann JJ. Depression. Lancet. 2018;392:2299–312.
World Health Organization. Depression and other common mental disorders: global health estimates. WHO/MSD/MER. 2017.2.
Lu J, Xu X, Huang Y, Li T, Ma C, Xu G, et al. Prevalence of depressive disorders and treatment in China: a cross-sectional epidemiological study. Lancet Psychiatry. 2021;8:981–90.
Wang Y, Wang G, Zhang N, Huang J, Wu W, Jia F, et al. Association between residual symptoms and social functioning in patients with depression. Compr Psychiatry. 2020;98: 152164.
Otte C, Gold SM, Penninx BW, Pariante CM, Etkin A, Fava M, et al. Major depressive disorder. Nat Rev Dis Primer. 2016;2:16065.
Perini G, Cotta Ramusino M, Sinforiani E, Bernini S, Petrachi R, Costa A. Cognitive impairment in depression: recent advances and novel treatments. Neuropsychiatr Dis Treat. 2019;15:1249–58.
Battle DE. Diagnostic and Statistical Manual of Mental Disorders (DSM). CoDAS. 2013;25:191–2.
Maor Y, Olmer L, Mozes B. The relation between objective and subjective impairment in cognitive function among multiple sclerosis patients–the role of depression. Mult Scler Houndmills Basingstoke Engl. 2001;7:131–5.
Srisurapanont M, Suttajit S, Eurviriyanukul K, Varnado P. Discrepancy between objective and subjective cognition in adults with major depressive disorder. Sci Rep. 2017;7:3901.
Srisurapanont M, Bautista D, Chen CH, Wang G, Udomratn P, Eurviriyanukul K. Subjective memory and concentration deficits in medication-free, non-elderly Asians with major depressive disorder: prevalence and their correlates. J Affect Disord. 2015;171:105–10.
McIntyre RS, Xiao HX, Syeda K, Vinberg M, Carvalho AF, Mansur RB, et al. The prevalence, measurement, and treatment of the cognitive dimension/domain in major depressive disorder. CNS Drugs. 2015;29:577–89.
Friedman NP, du Pont A, Corley RP, Hewitt JK. Longitudinal relations between depressive symptoms and executive functions from adolescence to early adulthood: a twin study. Clin Psychol Sci J Assoc Psychol Sci. 2018;6:543–60.
Kim JM, Chalem Y, di Nicola S, Hong JP, Won SH, Milea D. A cross-sectional study of functional disabilities and perceived cognitive dysfunction in patients with major depressive disorder in South Korea: The PERFORM-K study. Psychiatry Res. 2016;239:353–61.
Zhang H, Ding L, Shen T, Peng D. HMGB1 involved in stress-induced depression and its neuroinflammatory priming role: a systematic review. Gen Psychiatry. 2019;32: e100084.
Pape K, Tamouza R, Leboyer M, Zipp F. Immunoneuropsychiatry - novel perspectives on brain disorders. Nat Rev Neurol. 2019;15:317–28.
Chung W-S, Welsh CA, Barres BA, Stevens B. Do glia drive synaptic and cognitive impairment in disease? Nat Neurosci. 2015;18:1539–45.
Birdsall JW, Schmitz SL, Abosi OJ, DuBose LE, Pierce GL, Fiedorowicz JG. Inflammatory and vascular correlates of mood change over 8 weeks. Heart Mind Mumbai India. 2019;3:47–54.
Werf YDVD, Jongste MJLD, Horst GJT. The immune system mediates blood-brain barrier damage; possible implications for pathophysiology of neuropsychiatric illnesses. Acta Neuropsychiatr. 1995;7:114–21.
Calabrese F, Rossetti AC, Racagni G, Gass P, Riva MA, Molteni R. Brain-derived neurotrophic factor: a bridge between inflammation and neuroplasticity. Front Cell Neurosci. 2014;8:430.
Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med. 2009;71:171–86.
Lotrich FE, Butters MA, Aizenstein H, Marron MM, Reynolds CF, Gildengers AG. The relationship between interleukin-1 receptor antagonist and cognitive function in older adults with bipolar disorder. Int J Geriatr Psychiatry. 2014;29:635–44.
Zazula R, Dodd S, Dean OM, Berk M, Bortolasci CC, Verri WA, et al. Cognition-immune interactions between executive function and working memory, tumour necrosis factor-alpha (TNF-alpha) and soluble TNF receptors (sTNFR1 and sTNFR2) in bipolar disorder. World J Biol Psychiatry Off J World Fed Soc Biol Psychiatry. 2022;23:67–77.
Asevedo E, Gadelha A, Noto C, Mansur RB, Zugman A, Belangero SIN, et al. Impact of peripheral levels of chemokines, BDNF and oxidative markers on cognition in individuals with schizophrenia. J Psychiatr Res. 2013;47:1376–82.
Levada OA, Troyan AS. Insulin-like growth factor-1: a possible marker for emotional and cognitive disturbances, and treatment effectiveness in major depressive disorder. Ann Gen Psychiatry. 2017;16:38.
Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56–62.
Shi C, Wang G, Tian F, Han X, Sha S, Xing X, et al. Reliability and validity of Chinese version of perceived deficits questionnaire for depression in patients with MDD. Psychiatry Res. 2017;252:319–24.
Wang G, Si T-M, Li L, Fang Y, Wang C-X, Wang L-N, et al. Cognitive symptoms in major depressive disorder: associations with clinical and functional outcomes in a 6-month, non-interventional, prospective study in China. Neuropsychiatr Dis Treat. 2019;15:1723–36.
Petersen JZ, Porter RJ, Miskowiak KW. Clinical characteristics associated with the discrepancy between subjective and objective cognitive impairment in depression. J Affect Disord. 2019;246:763–74.
Conradi HJ, Ormel J, de Jonge P. Presence of individual (residual) symptoms during depressive episodes and periods of remission: a 3-year prospective study. Psychol Med. 2011;41:1165–74.
Svendsen AM, Kessing LV, Munkholm K, Vinberg M, Miskowiak KW. Is there an association between subjective and objective measures of cognitive function in patients with affective disorders? Nord J Psychiatry. 2012;66:248–53.
Rnic K, Jung Y-E, Torres I, Chakrabarty T, LeMoult J, Vaccarino AL, et al. Association between discrepancy in objective and subjective cognitive abilities and treatment response in patients with major depressive disorder: a CAN-BIND-1 study report. J Affect Disord. 2021;295:1095–101.
Miskowiak KW, Petersen JZ, Ott CV, Knorr U, Kessing LV, Gallagher P, et al. Predictors of the discrepancy between objective and subjective cognition in bipolar disorder: a novel methodology. Acta Psychiatr Scand. 2016;134:511–21.
Jin K, Lu J, Yu Z, Shen Z, Li H, Mou T, et al. Linking peripheral IL-6, IL-1β and hypocretin-1 with cognitive impairment from major depression. J Affect Disord. 2020;277:204–11.
Das R, Emon MPZ, Shahriar M, Nahar Z, Islam SMA, Bhuiyan MA, et al. Higher levels of serum IL-1β and TNF-α are associated with an increased probability of major depressive disorder. Psychiatry Res. 2021;295: 113568.
Nordengen K, Kirsebom B-E, Henjum K, Selnes P, Gísladóttir B, Wettergreen M, et al. Glial activation and inflammation along the Alzheimer’s disease continuum. J Neuroinflammation. 2019;16:46.
Diniz BS, Sibille E, Ding Y, Tseng G, Aizenstein HJ, Lotrich F, et al. Plasma biosignature and brain pathology related to persistent cognitive impairment in late-life depression. Mol Psychiatry. 2015;20:594–601.
Barroeta-Espar I, Weinstock LD, Perez-Nievas BG, Meltzer AC, Siao Tick Chong M, Amaral AC, et al. Distinct cytokine profiles in human brains resilient to Alzheimer’s pathology. Neurobiol Dis. 2019;121:327–37.
Leff Gelman P, Mancilla-Herrera I, Flores-Ramos M, Saravia Takashima MF, Cruz Coronel FM, Cruz Fuentes C, et al. The cytokine profile of women with severe anxiety and depression during pregnancy. BMC Psychiatry. 2019;19:104.
Myint A-M, Leonard BE, Steinbusch HWM, Kim Y-K. Th1, Th2, and Th3 cytokine alterations in major depression. J Affect Disord. 2005;88:167–73.
Deng Z, Deng S, Zhang MR, Tang MM. Fibroblast growth factors in depression. Front Pharmacol. 2019;10:60.
Feng Y-S, Tan Z-X, Wu L-Y, Dong F, Zhang F. The involvement of NLRP3 inflammasome in the treatment of Alzheimer’s disease. Ageing Res Rev. 2020;64: 101192.
Schmitt E, Klein M, Bopp T. Th9 cells, new players in adaptive immunity. Trends Immunol. 2014;35:61–8.
Marques RE, Guabiraba R, Russo RC, Teixeira MM. Targeting CCL5 in inflammation. Expert Opin Ther Targets. 2013;17:1439–60.
Bauer O, Milenkovic VM, Hilbert S, Sarubin N, Weigl J, Bahr L-M, et al. Association of Chemokine (C-C Motif) Receptor 5 and Ligand 5 with recovery from major depressive disorder and related neurocognitive impairment. NeuroImmunoModulation. 2020;27:152–62.
Sil S, Periyasamy P, Thangaraj A, Chivero ET, Buch S. PDGF/PDGFR axis in the neural systems. Mol Asp Med. 2018;62:63–74.
Nakamura K, Arimura K, Nishimura A, Tachibana M, Yoshikawa Y, Makihara N, et al. Possible involvement of basic FGF in the upregulation of PDGFRβ in pericytes after ischemic stroke. Brain Res. 2016;1630:98–108.
Benedetti F, Poletti S, Hoogenboezem TA, Locatelli C, Ambrée O, de Wit H, et al. Stem Cell Factor (SCF) is a putative biomarker of antidepressant response. J Neuroimmune Pharmacol. 2016;11:248–58.
Chen H, Teng Y, Chen X, Liu Z, Geng F, Liu Y, et al. Platelet-derived growth factor (PDGF)-BB protects dopaminergic neurons via activation of Akt/ERK/CREB pathways to upregulate tyrosine hydroxylase. CNS Neurosci Ther. 2021;27:1300–12.
Tseng HC, Dichter MA. Platelet-derived growth factor-BB pretreatment attenuates excitotoxic death in cultured hippocampal neurons. Neurobiol Dis. 2005;19:77–83.